Pelvic exenteration in the age of modern chemoradiation.
BACKGROUND
To examine outcomes after pelvic exenteration in women treated with modern chemoradiation and surgical techniques.


METHODS
All patients at our institution with a diagnosis of gynecologic malignancy who underwent pelvic exenteration after treatment with chemoradiation between 1/90 and 6/08 were evaluated with a retrospective chart review.


RESULTS
44 women were identified, of whom 29 (66%) had cervical, 6 (14%) had uterine, 5 (11%) had vaginal, and 4 (9%) had vulvar cancer. The majority of patients (82%) were initially treated with external beam whole-pelvic radiation with concurrent cisplatin. 38 patients (86%) underwent exenteration for a central pelvic recurrence, and the remaining 6 patients (14%) for radiation necrosis. The most common surgical complication was transfusion requirement in 36 patients (82%), followed by wound infection in 15 (34%), small bowel obstruction in 8 (18%), and sepsis in 6 (14%). The median time spent in the ICU post-operatively was 2 days. One patient (2%) died during her post-operative hospital stay. The mean EBL overall was 2497 cc and the mean operative time was 544 min. Use of electrothermal bipolar coagulation, which was used in 64% of the exenterations, significantly reduced blood loss (3679 cc vs. 1836 cc, p=0.014). After exenteration, 21 patients (48%) were diagnosed with a recurrence of cancer, and the mean progression free survival was 31 months. Patients who received exenteration less than 2 years after their initial chemoradiation had a significantly shorter overall survival time (8 months vs. 33 months, p=0.016).


CONCLUSIONS
Approximately 50% of women develop recurrence following exenterations done after chemoradiation. Survival is significantly longer in patients who necessitate exenteration greater than 2 years out from initial treatment. Electrothermal bipolar coagulation appears to significantly reduce blood loss during these surgeries.
Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA, USA. kamclean@u.washington.edu
Kate A
KA
McLean
Weiya
W
Zhang
Rebecca F
RF
Dunsmoor-Su
Chirag A
CA
Shah
Heidi J
HJ
Gray
Ron E
RE
Swensen
Barbara A
BA
Goff
D000328:Adult; D000368:Aged; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery*; D006801:Humans; D008136:Longevity; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D010385:Pelvic Exenteration / Q000379:methods*; D016879:Salvage Therapy; D015996:Survival Rate; D016896:Treatment Outcome